JP2002505294A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002505294A5 JP2002505294A5 JP2000534220A JP2000534220A JP2002505294A5 JP 2002505294 A5 JP2002505294 A5 JP 2002505294A5 JP 2000534220 A JP2000534220 A JP 2000534220A JP 2000534220 A JP2000534220 A JP 2000534220A JP 2002505294 A5 JP2002505294 A5 JP 2002505294A5
- Authority
- JP
- Japan
- Prior art keywords
- halo
- substituents
- alkyl
- embedded image
- alkanoyloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 C 1 -C 4 alkyl Chemical group 0.000 description 20
- 125000001475 halogen functional group Chemical group 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- NESIVXZOSKKUDP-ARVJLQODSA-N (4r,5s,6s,7r,9r,11e,13e,15r,16r)-6-[(2r,3r,4s,5s,6r)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-7-[2-[(3s,5r)-3,5-dimethylpiperidin-1-yl]ethyl]-16-ethyl-4-hydroxy-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-5,9,13 Chemical compound OP(O)(O)=O.O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O NESIVXZOSKKUDP-ARVJLQODSA-N 0.000 description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000001302 tertiary amino group Chemical group 0.000 description 2
- 229960000223 tilmicosin Drugs 0.000 description 2
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 description 2
- 229960000757 tilmicosin phosphate Drugs 0.000 description 2
- 0 CC(C(C(*)(C1)O)O)OC1OC Chemical compound CC(C(C(*)(C1)O)O)OC1OC 0.000 description 1
- 241000710788 Lelystad virus Species 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7646698P | 1998-03-02 | 1998-03-02 | |
| US60/076,466 | 1998-03-02 | ||
| PCT/US1999/004621 WO1999044619A1 (en) | 1998-03-02 | 1999-03-02 | Treatment of viral disease in swine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002505294A JP2002505294A (ja) | 2002-02-19 |
| JP2002505294A5 true JP2002505294A5 (enExample) | 2006-04-13 |
| JP4555472B2 JP4555472B2 (ja) | 2010-09-29 |
Family
ID=22132217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000534220A Expired - Fee Related JP4555472B2 (ja) | 1998-03-02 | 1999-03-02 | ブタのウイルス疾患の処置 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6034070A (enExample) |
| EP (1) | EP0948967B1 (enExample) |
| JP (1) | JP4555472B2 (enExample) |
| AT (1) | ATE281173T1 (enExample) |
| AU (1) | AU2979899A (enExample) |
| CA (1) | CA2322327C (enExample) |
| CO (1) | CO5080775A1 (enExample) |
| DE (1) | DE69921530T2 (enExample) |
| DK (1) | DK0948967T3 (enExample) |
| ES (1) | ES2230802T3 (enExample) |
| MY (1) | MY124071A (enExample) |
| PT (1) | PT948967E (enExample) |
| SI (1) | SI0948967T1 (enExample) |
| TW (1) | TW565452B (enExample) |
| WO (1) | WO1999044619A1 (enExample) |
| ZA (1) | ZA991641B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506885B1 (en) * | 2001-09-27 | 2003-01-14 | The United States Of America As Represented By The Secretary Of Agriculture | Monoclonal antibodies to the drug tilmicosin and a method for detecting the same |
| US6946137B2 (en) * | 2001-10-19 | 2005-09-20 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| CN1607937A (zh) * | 2001-10-19 | 2005-04-20 | 爱德士实验室公司 | 用于药理活性化合物的可控释放的可注射组合物 |
| ATE452896T1 (de) | 2002-03-12 | 2010-01-15 | Bristol Myers Squibb Co | C3-cyanoepothilonderivate |
| US7282487B2 (en) * | 2004-10-28 | 2007-10-16 | Idexx Laboratories | Method for treating bacterial infections in horses or pigs with tilmicosin |
| WO2008012343A2 (en) | 2006-07-28 | 2008-01-31 | Intervet International B.V. | Macrolide synthesis process |
| CN103288904B (zh) * | 2013-06-28 | 2015-07-15 | 宁夏泰瑞制药股份有限公司 | 一种磷酸替米考星晶体的制备方法 |
| CN103483406A (zh) * | 2013-09-25 | 2014-01-01 | 宁夏泰瑞制药股份有限公司 | 一种磷酸替米考星的制备方法 |
| CN103923141B (zh) * | 2014-04-21 | 2016-04-27 | 西南大学 | 一种依托替米考星的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL69666A (en) * | 1982-09-13 | 1987-10-20 | Lilly Co Eli | 20-amino-20-deoxo-5-o-mycaminosyl-23-o-mycinosyltylonolide derivatives,their preparation and veterinary antibiotic use |
| US4820695A (en) * | 1982-09-13 | 1989-04-11 | Eli Lilly And Company | C-20-dihydro-deoxy-(cyclic amino)-derivatives of macrolide antibiotics |
| US5574020A (en) * | 1989-09-28 | 1996-11-12 | Eli Lilly And Company | Tilmicosin formulation |
| US5695766A (en) * | 1992-10-30 | 1997-12-09 | Iowa State University Research Foundation | Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome |
| DK53595A (da) * | 1994-05-13 | 1995-11-14 | Iberica Cyanamid | Rekombinante PRRSV-proteiner, diagnostiske kits og vaccine indeholdende sådanne rekombinante PRRSV-proteiner |
| PT732340E (pt) * | 1995-03-14 | 2004-09-30 | Akzo Nobel Nv | Expressao de polipeptidos do virus da sindrome reprodutiva e respiratoria porcina na mesma celula |
-
1999
- 1999-03-01 DK DK99301503T patent/DK0948967T3/da active
- 1999-03-01 US US09/259,780 patent/US6034070A/en not_active Expired - Lifetime
- 1999-03-01 AT AT99301503T patent/ATE281173T1/de active
- 1999-03-01 ZA ZA9901641A patent/ZA991641B/xx unknown
- 1999-03-01 EP EP99301503A patent/EP0948967B1/en not_active Expired - Lifetime
- 1999-03-01 TW TW088103069A patent/TW565452B/zh not_active IP Right Cessation
- 1999-03-01 SI SI9930730T patent/SI0948967T1/xx unknown
- 1999-03-01 CO CO99012471A patent/CO5080775A1/es unknown
- 1999-03-01 DE DE69921530T patent/DE69921530T2/de not_active Expired - Lifetime
- 1999-03-01 ES ES99301503T patent/ES2230802T3/es not_active Expired - Lifetime
- 1999-03-01 PT PT99301503T patent/PT948967E/pt unknown
- 1999-03-01 MY MYPI99000736A patent/MY124071A/en unknown
- 1999-03-02 AU AU29798/99A patent/AU2979899A/en not_active Abandoned
- 1999-03-02 JP JP2000534220A patent/JP4555472B2/ja not_active Expired - Fee Related
- 1999-03-02 CA CA002322327A patent/CA2322327C/en not_active Expired - Fee Related
- 1999-03-02 WO PCT/US1999/004621 patent/WO1999044619A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003501474A5 (enExample) | ||
| BR0114323A (pt) | Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto | |
| CA2447175A1 (en) | Use of estrogen compounds to increase libido in women | |
| KR960700708A (ko) | 3,4-디아릴크로만을 이용한 뼈 손실의 억제방법(methdos for inhibiting bone loss with 3,4-diarylchroman) | |
| JP2002505294A5 (enExample) | ||
| JP3963976B2 (ja) | クラミジア感染症治療剤 | |
| JP2006508091A5 (enExample) | ||
| JP2006500394A5 (enExample) | ||
| CA2632626A1 (en) | Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection | |
| JP2005508961A5 (enExample) | ||
| SE0104334D0 (sv) | Therapeutic agents | |
| GB9900334D0 (en) | Tricylic vascular damaging agents | |
| JP2004537516A5 (enExample) | ||
| JPWO2020123827A5 (enExample) | ||
| RU2012110380A (ru) | Новое производное 5-фторурацила | |
| JP2003532640A5 (enExample) | ||
| JP2010505865A5 (enExample) | ||
| WO2013185301A1 (zh) | 黄酮及二氢黄酮衍生物在制备镇静、催眠药物中的用途 | |
| RU2002101622A (ru) | Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом | |
| JP2001513567A5 (enExample) | ||
| JP2008545695A5 (enExample) | ||
| RU2002102551A (ru) | Новые производные пиперазинилалкилтиопиримидина, содержащие их фармацевтические композиции и способ получения активного вещества | |
| CA2322327A1 (en) | Treatment of viral disease in swine | |
| JP2006503056A5 (enExample) | ||
| JP2008542386A5 (enExample) |